Trial Profile
Phase I study evaluating safety and tolerability of SurVaxM in patients with survivin-expressing recurrent malignant gliomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs SVN53-67-M57-KLH peptide vaccine (Primary)
- Indications Glioma
- Focus Adverse reactions
- 05 Apr 2017 Results assessing specific exosomes correlated with disease progression, presented at the 108th Annual Meeting of the American Association for Cancer Research
- 19 Aug 2015 New trial record